These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36159781)

  • 1. Roles of CD4+ T cells as mediators of antitumor immunity.
    Kravtsov DS; Erbe AK; Sondel PM; Rakhmilevich AL
    Front Immunol; 2022; 13():972021. PubMed ID: 36159781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4
    Wang B; Hu S; Fu X; Li L
    Adv Biol (Weinh); 2023 Apr; 7(4):e2200169. PubMed ID: 36193961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 cells can be more efficient at tumor rejection than CD8 cells.
    Perez-Diez A; Joncker NT; Choi K; Chan WF; Anderson CC; Lantz O; Matzinger P
    Blood; 2007 Jun; 109(12):5346-54. PubMed ID: 17327412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
    Wang LX; Shu S; Disis ML; Plautz GE
    Blood; 2007 Jun; 109(11):4865-76. PubMed ID: 17284532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4
    Jeong S; Jang N; Kim M; Choi IK
    BMB Rep; 2023 Mar; 56(2):140-144. PubMed ID: 36863358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity.
    Meng F; Zhen S; Song B
    APMIS; 2017 Aug; 125(8):743-751. PubMed ID: 28493520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic CD4
    Oh DY; Fong L
    Immunity; 2021 Dec; 54(12):2701-2711. PubMed ID: 34910940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
    Chhabra A
    Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of antigen-specific CD8+ CTL in MHC class I-deficient mice through CD4 to CD8 conversion.
    Tanaka Y; Koido S; Xia J; Ohana M; Liu C; Cote GM; Sawyer DB; Calderwood S; Gong J
    J Immunol; 2004 Jun; 172(12):7848-58. PubMed ID: 15187169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloantigen-activated (AAA) CD4
    Mochizuki K; Kobayashi S; Takahashi N; Sugimoto K; Sano H; Ohara Y; Mineishi S; Zhang Y; Kikuta A
    J Exp Clin Cancer Res; 2021 Oct; 40(1):314. PubMed ID: 34625113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
    Kennedy RC; Shearer MH; Watts AM; Bright RK
    Cancer Res; 2003 Mar; 63(5):1040-5. PubMed ID: 12615720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
    Zeng G
    J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
    Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.